

27. (Twice Amended) An isolated polypeptide comprising a member selected from the group consisting of

- C²
- (a) SEQ ID NO:2;
 - (b) an immunogenic fragment of SEQ ID NO:2, wherein the immunogenic fragment comprises at least 15 amino acids;

wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell immune response to a polypeptide consisting of SEQ ID NO:2.

28. The isolated polypeptide of claim 27, wherein the polypeptide is according to (a).

29. The isolated polypeptide of claim 27, wherein the polypeptide is according to (b).

31. The isolated polypeptide of claim 27, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.

C³

34. (Twice Amended) The isolated polypeptide of claim 27, wherein the isolated polypeptide consists of SEQ ID NO:2.

35. A fusion protein comprising the isolated polypeptide of Claim 27.

C⁴

53. (Once Amended) An immunogenic composition comprising the polypeptide of Claim 27 and a pharmaceutically acceptable carrier.

C⁵

62. (New) The isolated polypeptide of claim 29, wherein the immunogenic fragment of (b) comprises amino acids 47-59 of SEQ ID NO:2.

63. (New) The isolated polypeptide of claim 29, wherein the immunogenic fragment of (b) comprises amino acids 158-172 of SEQ ID NO:2.

DOCKET NO. BM45311
SERIAL NO. 09/674,779

64. (New) The isolated polypeptide of claim 27, wherein the isolated polypeptide consists of amino acids 158-172 of SEQ ID NO:2.
-